Supporting the group's sustainable growth and building the future with peace of mind

One group, four poles

Life Science

Created by Dr Rolland-Yves Mauvernay in 1979 and joined by his son Thierry Mauvernay in 2001, Debiopharm consolidates its expertise in the development of innovative therapies in oncology and infectious diseases.

Responsible Capital Management

In the early 2000s, an asset diversification division was developed to generate additional income and mitigate the risks of Debiopharm's activities.



Starting from 2010, the group began to support various philanthropic projects locally and internationally.


Impactful Capital Management

In 2020, founded on the group's success, a new division was created to address two major challenges: climate revolution and people living in precarious circumstances.


Our ambition

  • A positive impact on lives through life science, by improving the patient treatment journey in the field of oncology and bacterial infections.

  • Our shared values:
    Agility. Efficiency. Passion. Ethics. Creativity. Commitment.

  • More meaning to investments by contributing  to the improvement of the environment, education, nutrition, housing, leisure and social services.


Discover the members who guide and bring long-term vision to Après-demain SA

Press Releases

Discover the latest Après-demain news

Press releases